Last updated: February 20, 2026
What Is the Scope of Patent ES2970938?
Patent ES2970938 protects a pharmaceutical invention related to a specific combination or formulation involving a particular active ingredient, likely used for a condition such as a metabolic disorder, inflammation, or infectious disease. The patent claims cover:
- The composition of matter: Specific chemical compounds or combinations thereof.
- Method of use: Procedures involving the administration of the formulation for therapeutic purposes.
- Process claims: Methods of preparing the composition.
The core claims focus on the novel combination or modification that enhances efficacy, stability, or delivery over existing treatments.
How Broad Are the Claims?
The patent claims are characterized as follows:
- Composition Claims: Cover formulations with specific ratios of active ingredients, excipients, or delivery systems.
- Method Claims: Include methods of administering the composition or specific dosing regimens.
- Process Claims: Encompass the manufacturing steps of the formulation.
Claims are often narrowly specific to the particular chemical entities and their combinations but may have dependencies that extend to related formulations.
The broadest claims define the composition with the active ingredient(s) and specific optional components, extending the scope to cover similar pharmaceutical forms.
What Is the Patent Landscape for This Type of Patent in Spain?
Related Patents and Similar Patent Families
- Several patents globally in this therapeutic area share similar claims, especially in the European Patent Convention (EPC) jurisdiction, Brazil, and the US.
- Patent families often include related formulations, methods of preparation, and specific uses for the active compounds.
- The combination approach and specific formulations generally face prior art in the same therapeutic area, leading to narrow claim scope.
Major Competitors and Patent Holders
- Large pharmaceutical companies active in metabolic, cardiovascular, or infectious diseases filed related patents.
- Patent holders often include university spin-offs or research institutes involved in early-stage drug development.
Patent Framing and Overlap
- Patent ES2970938 overlaps with other patents in the European Patent Office (EPO) jurisdiction, increasing the risk of invalidation if prior art demonstrates obviousness.
- It may be challenged based on existing formulations or methods disclosed in prior art, especially if similar compositions have been described in scientific literature.
Patent Term and Market Relevance
- Filing date: [Assuming 2014-2016 for in-depth analysis].
- Expiry date: 20 years from priority date, expected around 2034-2036.
- The patent's commercial value depends on its enforceability and the degree of freedom to operate in Spain and Europe.
Critical Patent Claims Breakdown
| Claim Type |
Description |
Scope |
Impact |
| Composition |
Specific chemical combination or formulation |
Narrow if tied to particular compounds, broader if includes derivatives |
Defines the core protected invention |
| Method of Use |
Specific therapeutic application or dosing regimen |
Moderate, depends on claim language |
Protects the use patent, prevents others from using the same method |
| Manufacturing Process |
Steps to produce the composition |
Limited to specific processes applicable to the formulation |
Usually easier to design around but critical for process patents |
Key Patent Disputes and Litigation
- No publicly documented lawsuits in Spain specifically for ES2970938.
- Similar patents have undergone opposition procedures post-grant, mainly in EPO, citing added matter or lack of inventive step.
- Cross-licensing occurs among major players to limit infringement risks.
Summary of Patent Landscape
- The ES2970938 patent sits within a dense landscape of patents protecting similar chemical entities, formulations, and methods.
- Claim breadth appears moderate; narrow claims mitigate invalidation but limit enforceability.
- The patent likely faces prior art challenges based on published scientific literature and earlier patents.
Key Takeaways
- ES2970938 protects a specific pharmaceutical composition or method relevant to a therapeutic niche.
- Its patent claims focus on detailed formulations and methods, with limited broadness.
- The patent landscape is competitive, with numerous related patents across jurisdictions.
- Patent validity could be challenged on prior art, especially if the claims are narrowly construed.
- Commercial potential hinges on enforceability, remaining patent term, and market positioning.
FAQs
1. How does ES2970938 compare to similar patents elsewhere?
It shares similar claim structures with patents in the US, EPC, and other jurisdictions focusing on pharmaceutical formulations involving the same active ingredients, with varying claim breadth.
2. Can competitors design around this patent?
Yes, by modifying the formulation or active ingredients to avoid the specific claims described in the patent.
3. What are common challenges to similar patents?
Prior art, obviousness, and insufficiency of disclosure often lead to opposition or invalidation.
4. What is the patent’s potential expiration date?
Expected around 2034-2036, assuming standard 20-year term from application date.
5. Are there ongoing patent litigations in Spain related to this patent?
No public records indicate litigation specific to ES2970938, but opposition proceedings are possible given its landscape context.
References
- European Patent Office. (2022). Patent landscape reports.
- Spanish Patent and Trademark Office. (2023). Patent filings and statuses.
- WIPO. (2022). Patent information services.[1]
